Linked Life Data

18988129

Source:http://linkedlifedata.com/resource/pubmed/id/18988129

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
46
pubmed:dateCreated
2008-11-6
pubmed:abstractText
Myasthenia gravis in the majority of patients is a well treatable neurological autoimmune disorder with a prevalence of 60-150 per million. For the treatment of myasthenic crisis in the intensive care unit the use of therapeutic apheresis, e. g. immunoadsorption or plasma exchange, is well established due to its rapid therapeutic effect, whereas the necessity in long term treatment is still questioned. Aim of this retrospective cohort-study was the assessment of patients with refractory myasthenia gravis in Germany treated by regular immunoadsorption, the characterization of previous therapies and the efficacy of long-term treatment.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1439-4413
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
133
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2377-82
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
[Long-term treatment of refractory myasthenia gravis with immunoadsorption].
pubmed:affiliation
Medizinische Klinik II, Schwerpunkt für Nephrologie, Hochdruck und Gefässkrankheiten, Markuskrankenhaus, Frankfurt/Main. wagner.stephan@phv-dialyse.de
pubmed:publicationType
Journal Article, English Abstract, Evaluation Studies